PYC Therapeutics Limited
PYCXF
$0.8462
$0.178626.75%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -2.75% | -8.49% | |||
| Total Revenue | -2.75% | -8.49% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.75% | -8.49% | |||
| SG&A Expenses | -2.74% | 42.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | 7.12% | |||
| Operating Income | 2.75% | -15.88% | |||
| Income Before Tax | 2.75% | -15.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | -15.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -2.75% | 33.56% | |||
| Net Income | 2.75% | -14.90% | |||
| EBIT | 2.75% | -15.88% | |||
| EBITDA | 2.75% | -16.60% | |||
| EPS Basic | 2.72% | -1.10% | |||
| Normalized Basic EPS | 2.63% | -0.88% | |||
| EPS Diluted | 2.72% | -1.10% | |||
| Normalized Diluted EPS | 2.63% | -0.88% | |||
| Average Basic Shares Outstanding | 0.00% | 13.87% | |||
| Average Diluted Shares Outstanding | 0.00% | 13.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||